Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial

Table 3 Exploratory subgroup analysis of progression-free survival (n = 61)

		N	PFS (months)	Ratio (CI)	P	HR (CI)
Gender	Female	49	13.2	1.56 (1.101–2.023)	0.447	0.719 (0.305–1.696)
Gender	Male	12	8.45	1.56 (1.101–2.023)	0.447	0.719 (0.305–1.696)
Age	≤70	31	11.7	0.76 (0.225–1.294)	0.164	1.561 (0.834–2.922)
Age	> 70	30	15.4	0.76 (0.225–1.294)	0.164	1.561 (0.834–2.922)
Smoking	Never	41	15.4	0.545 (0.018–1.073)	0.045	2.118 (1.016–4.418)
Smoking	Ever	20	8.4	0.545 (0.018–1.073)	0.045	2.118 (1.016–4.418)
Mutation	Exon 19	37	13	0.79 (0.266–1.320)	0.607	1.186 (0.627–2.243)
Mutation	Exon 21	24	16.4	0.79 (0.266–1.320)	0.607	1.186 (0.627–2.243)
ECOG	0	24	18.9		0.017
	1	31	12.6
	2	6	4.4
Stage^a	M1a	31	18.9	2.22 (1.708–2.739)	0.002	0.334 (0.167–0.672)
Stage^a	M1b	24	8.5	2.22 (1.708–2.739)	0.002	0.334 (0.167–0.672)

ISSN: 1471-2407